Post by
FootballFan1 on Mar 02, 2016 7:35pm
Did CXR Overpay for Amdipharm Mercury...?
From the CXR press release dated September 8, 2015: "The total purchase price will consist of cash consideration of approximately 800 million (approximately US$1.2 billion), 8.49 million common shares of Concordia (approximately US$0.7 billion), and the assumption of approximately US$1.4 billion AMCo net debt upon closing, as well as a maximum performance-based earn-out of 144 million payable in cash in the fourth quarter of 2016 (approximately US$220 million). Following the closing of the transaction, Concordia will own a 100% stake in AMCo, and Cinven will hold an expected 19.9% ownership in Concordia on a non-diluted basis and before giving effect to the anticipated equity offering."
Comment by
pineapple1 on Mar 02, 2016 7:58pm
This post has been removed in accordance with Community Policy
Comment by
sunshine7 on Mar 03, 2016 11:19am
seems there is a concerted effort to bury good information under a pile of meaningless garbage posts. Well, to the top of the pile with this one and please refrain from personal attacks and responding to such. It will go a long way to improving the image of this board.
Comment by
Lumberfeverlong on Mar 03, 2016 7:41pm
Thank you for posting. This is a reasonable take on CXR debt levels and valuation. Earnings in a couple of weeks will provide the clarity we all seek. If guidance is met or exceeded and company announces further debt repayments, this stock should see a nice and steady climb above $60 in a relatively short period of time.
Comment by
adamchess on Mar 03, 2016 11:40pm
I believe Bruce Campbell's fund had a significant holding of Concordia after this article was written - meaning they were not too concerned with the debt at the time. His investments are more concervative now with a large holding of cash last time he was on BNN.